RT Journal Article
SR Electronic
T1 Phase II Clinical trial for Evaluation of BCG as potential therapy for COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.28.20221630
DO 10.1101/2020.10.28.20221630
A1 Padmanabhan, Usha
A1 Mukherjee, Sanjay
A1 Borse, Rohidas
A1 Joshi, Sameer
A1 Deshmukh, Rajesh
YR 2020
UL http://medrxiv.org/content/early/2020/11/03/2020.10.28.20221630.abstract
AB Bacillus Calmette−Guérin (BCG) is widely used in national vaccination programs worldwide. It is accepted that BCG alleviates both pathogen and allergy induced respiratory diseases that could also include Covid-19. To investigate this possibility, we randomly assigned 60 Covid-19 patients, after admission to the hospital with pneumonia and requirement for oxygen therapy in a 1:1 ratio to receive either a single adult dose of intradermal BCG or normal saline with concomitant standard of care (SoC) medications. Primary endpoints were favorable prognosis of Covid-19 as deduced from resolution of pneumonia, viremia and secondary outcome were enumeration of ICU admissions, duration thereof and mortalities.Results Both primary and secondary endpoints were significantly improved in the BCG+SoC group. This could be seen from reduction in oxygen requirement due to Covid-19 associated pneumonia decreasing from day 3-4, improved radiological resolution from day 7-15. There were a total of 6 (10%) adverse events in the study of which 2 deaths and 4 ICU admissions were in SoC group (1 ICU admission culminated in death of the subject) and in contrast only 1 ICU admission in the BCG+SoC group. While there was an increase in Covid-19 specific IgG levels in the BCG+SoC group, there was no evidence of BCG induced cytokine storm in this group. Four patients showed localized inflammatory response at the injection site in the BCG+SoC group.Conclusions BCG+SoC administration resulted in a significantly higher percentage of patients with favorable outcomes than did SoC. A third of the patients were naïve for childhood BCG vaccination. This mimicked elderly patients in countries with no universal vaccination policy for BCG. No BCG related adversity was seen in this group. The study shows that BCG is a safe, cost-effective treatment that can be introduced as a standard of care in patients with moderate Covid-19 that can reduce requirement of oxygen supplemented beds and disease burden in low resource countries, with additional long-term benefits of reducing risk for tuberculosis.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialCTRI/2020/05/025013Funding StatementThe study was sponsored through permissions and grants from Medical Education & Drugs Department (MEDD), Govt. of Maharashtra and from M/S Icertis Solutions Private Ltd, respectively.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of BJMC & Sassoon General Hospital no. BJMC/IEC/pharmac/ND0420059-059 dated 17.04.2020All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript will be provided after due permission from the State Government of Maharashtra after publication and submission to the Drug Controller General of India. Data when provided will be on a case to case basis and for research purposes only.